Klk5 inhibitory peptide
AssigneeDaiichi Sankyo Company, Limited
InventorsDaisuke Nishimiya, Hidenori Yano, Hidenori Takahashi, Shinji Yamaguchi, Shiho Ofuchi
Life of this patent
Estimating the term…
Loading patent…
AssigneeDaiichi Sankyo Company, Limited
InventorsDaisuke Nishimiya, Hidenori Yano, Hidenori Takahashi, Shinji Yamaguchi, Shiho Ofuchi
Estimating the term…
SPINK2 mutant peptide conjugates are provided that inhibit KLK5. The KLK5 inhibitory peptide conjugates are Fc fusion peptides in which, in certain embodiments, the Fc region of the fusion peptides are the Fc region of human IgG1 or a fragment thereof. The KLK5 inhibitory peptide conjugates include an amino acid sequence of one of SEQ ID NOs: 34, 36, 38, 40, 42, 44, 46, 48, 96, 50, 52, 54, 56, 58, or 60. Pharmaceutical compositions that include the KLK5 inhibitory peptide conjugates useful for treating KLK5-related diseases are also provided.
A polynucleotide comprising a nucleotide sequence encoding the amino acid sequence contained in a SPINK2 mutant peptide that inhibits the protease activity of active human KLK5, wherein the peptide comprises:
A polynucleotide comprising a nucleotide sequence encoding the amino acid sequence contained in a conjugate, wherein the conjugate comprises:
Dependencies are inferred from the claim text.